Comparison of MAFLD and NAFLD diagnostic criteria in real world

Metabolic associated fatty liver disease (MAFLD) is a novel concept proposed in 2020, the utility of which has not been tested and validated in real world. We aimed to compare the characteristics of MAFLD and non‐alcoholic fatty liver disease (NAFLD).

[1]  A. Dhawan,et al.  NAFLD to MAFLD in adults but the saga continues in children: an opportunity to advocate change.: Letter regarding "A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement". , 2021, Journal of hepatology.

[2]  S. Pelusi,et al.  Redefining fatty liver disease classification in 2020 , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[3]  The Lancet Gastroenterology & Hepatology.  Redefining non-alcoholic fatty liver disease: what's in a name? , 2020, The lancet. Gastroenterology & hepatology.

[4]  S. Bollipo,et al.  What's in a name? Renaming ‘NAFLD’ to ‘MAFLD’ , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[5]  A. Sanyal,et al.  MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. , 2020, Gastroenterology.

[6]  Yuxiu Liu,et al.  Association between Vitamin D Status and Non-Alcoholic Fatty Liver Disease: A Population-Based Study. , 2019, Journal of nutritional science and vitaminology.

[7]  Rohit Loomba,et al.  Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease. , 2019, Gastroenterology.

[8]  Jiaofeng Huang,et al.  Is Toxoplasma gondii infection correlated with nonalcoholic fatty liver disease?- a population-based study , 2018, BMC Infectious Diseases.

[9]  Y. Liu,et al.  Letter: significant burden of nonalcoholic fatty liver disease with advanced fibrosis in the USA: a cross‐sectional analysis of 2011‐2014 National Health and Nutrition Examination Survey , 2018, Alimentary pharmacology & therapeutics.

[10]  S. Bertrais,et al.  Screening for therapeutic trials and treatment indication in clinical practice: MACK‐3, a new blood test for the diagnosis of fibrotic NASH , 2018, Alimentary pharmacology & therapeutics.

[11]  Q. Anstee,et al.  The bidirectional impacts of alcohol consumption and the metabolic syndrome: Cofactors for progressive fatty liver disease. , 2018, Journal of hepatology.

[12]  L. Henry,et al.  NAFLD AND NASH: Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention , 2018 .

[13]  A. Diehl,et al.  Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis , 2017, The New England journal of medicine.

[14]  S. Sookoian,et al.  Nonalcoholic fatty liver disease and metabolic syndrome: Shared genetic basis of pathogenesis , 2016, Hepatology.

[15]  Dongfeng Chen,et al.  Comparison of FIB‐4 index, NAFLD fibrosis score and BARD score for prediction of advanced fibrosis in adult patients with non‐alcoholic fatty liver disease: A meta‐analysis study , 2016, Hepatology research : the official journal of the Japan Society of Hepatology.

[16]  L. Henry,et al.  Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes , 2016, Hepatology.

[17]  H. Tilg,et al.  EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease , 2016, Obesity Facts.

[18]  European Association for the Study of the Liver,et al.  EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease , 2016, Obesity Facts.

[19]  M. Chonchol,et al.  Association between Nonalcoholic Liver Disease and Chronic Kidney Disease: An Ultrasound Analysis from NHANES 1988–1994 , 2012, American Journal of Nephrology.

[20]  Chris Day,et al.  A position statement on NAFLD/NASH based on the EASL 2009 special conference. , 2010, Journal of hepatology.

[21]  T. Therneau,et al.  The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD , 2007, Hepatology.

[22]  J. Montaner,et al.  Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection , 2006, Hepatology.